ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0733

Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 1007

Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0747

Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0926

Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0915

Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 1017

Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0975

Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0646

Modulation of Type I IFN Production and Regulatory T Cells by the PKGI/ROCK Signaling Pathway

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0590

Molecular Profiling of Normal Human Synovium Reveals Striking Impact of Adipocytes and Homeostatic Cortisol Signaling

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0581

Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders

Cytokines and Cell Trafficking Poster

9:00AM-10:30AM: Abstract Number: 1048

Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0620

Neovascularization Is Altered by Rheumatoid Arthritis Synovial Fibroblasts and Canstatin in Vitro and in Vivo

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0968

Neuropsychological Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-administered Multidisciplinary Questionnaire in a Monocentric Cohort

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0596

Neutrophil Extracellular Traps (NET) Trigger an Enhanced Pro-inflammatory Response in Macrophage Subpopulations in Rheumatoid Arthritis Patients via the Aryl Hydrocarbon Receptor (AhR) Pathway

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0877

Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster I: JIA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].